Unternehmen Black Diamond Therapeutics, Inc. OTC Markets
Aktien
A2PYWB
US09203E1055
BDTX
Biotechnologie
Verzögert
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
- USD | -.--% | -.--% | -.--% |
Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Elizabeth Buck
FOU | Founder | 49 | 01.01.14 |
Mark Velleca
CEO | Chief Executive Officer | 60 | 09.08.21 |
David Epstein
FOU | Founder | 65 | 01.01.14 |
Fang Ni
DFI | Director of Finance/CFO | 37 | 04.08.20 |
Sergey Yurasov
CTO | Chief Tech/Sci/R&D Officer | 55 | 01.06.22 |
Chief Operating Officer | 59 | 29.05.19 | |
Julie Seidel
IRC | Investor Relations Contact | - | - |
Melanie Morrison
PRN | Corporate Officer/Principal | 49 | 01.10.22 |
Human Resources Officer | 52 | 22.02.22 | |
Erika Jones
AUD | Comptroller/Controller/Auditor | 39 | 01.10.19 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
David Epstein
FOU | Founder | 65 | 01.01.14 |
Mark Velleca
CEO | Chief Executive Officer | 60 | 09.08.21 |
Ali Behbahani
BRD | Director/Board Member | 48 | 01.12.18 |
Garry Menzel
BRD | Director/Board Member | 59 | 01.01.14 |
Kapil Dhingra
BRD | Director/Board Member | 64 | 19.01.21 |
Samarth Kulkarni
BRD | Director/Board Member | 45 | 01.12.19 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 56 252 794 | 54 935 052 ( 97,66 %) | 0 | 97,66 % |
Unternehmenskontakt
Black Diamond Therapeutics, Inc.
One Main Street 14th floor
02142, Cambridge
+
http://www.blackdiamondtherapeutics.comSektor
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+16.73% | 123 Mrd. | |
+13.04% | 107 Mrd. | |
-5.80% | 24.01 Mrd. | |
+3.11% | 22.59 Mrd. | |
-10.09% | 18.16 Mrd. | |
-40.52% | 16.84 Mrd. | |
-14.00% | 16.23 Mrd. | |
+1.18% | 13.43 Mrd. | |
+24.18% | 11.32 Mrd. |
- Börse
- Aktien
- A2PYWB Aktie
- A2PYWB Aktie
- Unternehmen Black Diamond Therapeutics, Inc.